142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding
Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2020-06, Vol.69 (Supplement_1) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Supplement_1 |
container_start_page | |
container_title | Diabetes (New York, N.Y.) |
container_volume | 69 |
creator | COSGROVE, RICHARD ANTONELLIS, MEGHAN P. DROZ, BRIAN ROELL, WILLIAM C. SLOOP, KYLE MOYERS, JULIE COGHLAN, MATTHEW P. EMMERSON, PAUL COSKUN, TAMER SAMMS, RICARDO J. |
description | Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake. |
doi_str_mv | 10.2337/db20-142-OR |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419451227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419451227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c647-3e701db38663b340c9aadf652af76c04978640e70710001725cfaa0e33cee5263</originalsourceid><addsrcrecordid>eNotkU1PAjEQhhujiYie_ANNPEq1H8uW9UaQrwQC2XDwtintLCmBLbYlfvwb_6lFzBzmME-eNzOD0D2jT1wI-WzWnBKWcbIoL1CLFaIggsu3S9SilHHCZCGv0U0IW0ppnqqFfs70C15Z_w0HFa2BDlb49ah2eDxdYtUYPJ4tCcMlaDhE53F_4xobYgfPwVgVIeBpDLjfOA-fdgON1XhY16Ajtg2eWw3JBji6pC3BHHW0rjmNJm4PLsSUqf9iSvhQ3pASdklq8AiSvtncoqta7QLc_fc2Wo2Gq8GEzBbj6aA_IzrPJBEgKTNr0ctzsRYZ1YVSps67XNUy1zQrZC_PaIIkS7szybu6VoqCEBqgy3PRRg9n7cG79yOEWG3d0TcpseIZK7Iu41wm6vFMae9C8FBXB2_3yn9VjFanF1SnF1TpqNWiFL-qZnc8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419451227</pqid></control><display><type>article</type><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</creator><creatorcontrib>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</creatorcontrib><description>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db20-142-OR</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Agonists ; Antidiabetics ; Body weight ; Body weight loss ; Calories ; Diabetes mellitus (non-insulin dependent) ; Diet ; Energy intake ; Feeding behavior ; Food intake ; Fructose ; High fat diet ; Hunger ; Low fat diet ; Nutrient deficiency ; Obesity ; Reinforcement ; Satiety ; Sucralose ; Sucrose ; Tastants</subject><ispartof>Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>COSGROVE, RICHARD</creatorcontrib><creatorcontrib>ANTONELLIS, MEGHAN P.</creatorcontrib><creatorcontrib>DROZ, BRIAN</creatorcontrib><creatorcontrib>ROELL, WILLIAM C.</creatorcontrib><creatorcontrib>SLOOP, KYLE</creatorcontrib><creatorcontrib>MOYERS, JULIE</creatorcontrib><creatorcontrib>COGHLAN, MATTHEW P.</creatorcontrib><creatorcontrib>EMMERSON, PAUL</creatorcontrib><creatorcontrib>COSKUN, TAMER</creatorcontrib><creatorcontrib>SAMMS, RICARDO J.</creatorcontrib><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><title>Diabetes (New York, N.Y.)</title><description>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</description><subject>Agonists</subject><subject>Antidiabetics</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Calories</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diet</subject><subject>Energy intake</subject><subject>Feeding behavior</subject><subject>Food intake</subject><subject>Fructose</subject><subject>High fat diet</subject><subject>Hunger</subject><subject>Low fat diet</subject><subject>Nutrient deficiency</subject><subject>Obesity</subject><subject>Reinforcement</subject><subject>Satiety</subject><subject>Sucralose</subject><subject>Sucrose</subject><subject>Tastants</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkU1PAjEQhhujiYie_ANNPEq1H8uW9UaQrwQC2XDwtintLCmBLbYlfvwb_6lFzBzmME-eNzOD0D2jT1wI-WzWnBKWcbIoL1CLFaIggsu3S9SilHHCZCGv0U0IW0ppnqqFfs70C15Z_w0HFa2BDlb49ah2eDxdYtUYPJ4tCcMlaDhE53F_4xobYgfPwVgVIeBpDLjfOA-fdgON1XhY16Ajtg2eWw3JBji6pC3BHHW0rjmNJm4PLsSUqf9iSvhQ3pASdklq8AiSvtncoqta7QLc_fc2Wo2Gq8GEzBbj6aA_IzrPJBEgKTNr0ctzsRYZ1YVSps67XNUy1zQrZC_PaIIkS7szybu6VoqCEBqgy3PRRg9n7cG79yOEWG3d0TcpseIZK7Iu41wm6vFMae9C8FBXB2_3yn9VjFanF1SnF1TpqNWiFL-qZnc8</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>COSGROVE, RICHARD</creator><creator>ANTONELLIS, MEGHAN P.</creator><creator>DROZ, BRIAN</creator><creator>ROELL, WILLIAM C.</creator><creator>SLOOP, KYLE</creator><creator>MOYERS, JULIE</creator><creator>COGHLAN, MATTHEW P.</creator><creator>EMMERSON, PAUL</creator><creator>COSKUN, TAMER</creator><creator>SAMMS, RICARDO J.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200601</creationdate><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><author>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c647-3e701db38663b340c9aadf652af76c04978640e70710001725cfaa0e33cee5263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agonists</topic><topic>Antidiabetics</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Calories</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diet</topic><topic>Energy intake</topic><topic>Feeding behavior</topic><topic>Food intake</topic><topic>Fructose</topic><topic>High fat diet</topic><topic>Hunger</topic><topic>Low fat diet</topic><topic>Nutrient deficiency</topic><topic>Obesity</topic><topic>Reinforcement</topic><topic>Satiety</topic><topic>Sucralose</topic><topic>Sucrose</topic><topic>Tastants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COSGROVE, RICHARD</creatorcontrib><creatorcontrib>ANTONELLIS, MEGHAN P.</creatorcontrib><creatorcontrib>DROZ, BRIAN</creatorcontrib><creatorcontrib>ROELL, WILLIAM C.</creatorcontrib><creatorcontrib>SLOOP, KYLE</creatorcontrib><creatorcontrib>MOYERS, JULIE</creatorcontrib><creatorcontrib>COGHLAN, MATTHEW P.</creatorcontrib><creatorcontrib>EMMERSON, PAUL</creatorcontrib><creatorcontrib>COSKUN, TAMER</creatorcontrib><creatorcontrib>SAMMS, RICARDO J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COSGROVE, RICHARD</au><au>ANTONELLIS, MEGHAN P.</au><au>DROZ, BRIAN</au><au>ROELL, WILLIAM C.</au><au>SLOOP, KYLE</au><au>MOYERS, JULIE</au><au>COGHLAN, MATTHEW P.</au><au>EMMERSON, PAUL</au><au>COSKUN, TAMER</au><au>SAMMS, RICARDO J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db20-142-OR</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-1797 |
ispartof | Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) |
issn | 0012-1797 1939-327X |
language | eng |
recordid | cdi_proquest_journals_2419451227 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Agonists Antidiabetics Body weight Body weight loss Calories Diabetes mellitus (non-insulin dependent) Diet Energy intake Feeding behavior Food intake Fructose High fat diet Hunger Low fat diet Nutrient deficiency Obesity Reinforcement Satiety Sucralose Sucrose Tastants |
title | 142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T23%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=142-OR:%20Tirzepatide,%20a%20Dual%20GIP%20and%20GLP-1%20Receptor%20Agonist,%20Mediates%20Its%20Anorexigenic%20Effect%20in%20Mice%20Due%20to%20a%20Reduction%20in%20Homeostatic%20and%20Reward-Related%20Feeding&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=COSGROVE,%20RICHARD&rft.date=2020-06-01&rft.volume=69&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db20-142-OR&rft_dat=%3Cproquest_cross%3E2419451227%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419451227&rft_id=info:pmid/&rfr_iscdi=true |